ANDROGEL (testosterone) by Besins Healthcare is androgen receptor agonists [moa]. First approved in 2000.
Drug data last refreshed 1h ago · AI intelligence enriched Yesterday
ANDROGEL is a transdermal gel formulation of testosterone approved in 2000 for hormone replacement therapy in hypogonadal men. It works as an androgen receptor agonist to restore physiologic testosterone levels. The product is administered topically, providing steady-state hormone delivery.
Product in late-stage lifecycle with low Part D claims (1,947 in 2023) and $2M spending, suggesting smaller team size and transition focus.
Androgen Receptor Agonists
Androgen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Worked on ANDROGEL at Besins Healthcare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ANDROGEL offers exposure to mature product management and competitive defense strategies in a high-scrutiny therapeutic area with significant cardiovascular safety considerations. Career growth on this product will focus on lifecycle extension, generic competition mitigation, and market access rather than innovation or expansion.